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Abstract
Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with chronic kid-
ney disease (CKD). In this study, we examined the association between inflammation and
AF in 3,762 adults with CKD, enrolled in the Chronic Renal Insufficiency Cohort (CRIC)
study. AF was determined at baseline by self-report and electrocardiogram (ECG). Plasma
concentrations of interleukin(IL)-1, IL-1 Receptor antagonist, IL-6, tumor necrosis factor
(TNF)-α, transforming growth factor-β, high sensitivity C-Reactive protein, and fibrinogen,
measured at baseline. At baseline, 642 subjects had history of AF, but only 44 had AF in
ECG recording. During a mean follow-up of 3.7 years, 108 subjects developed new-onset
AF. There was no significant association between inflammatory biomarkers and past history
of AF. After adjustment for demographic characteristics, comorbid conditions, laboratory
values, echocardiographic variables, and medication use, plasma IL-6 level was signifi-
cantly associated with presence of AF at baseline (Odds ratio [OR], 1.61; 95% confidence
interval [CI], 1.21 to 2.14; P = 0.001) and new-onset AF (OR, 1.25; 95% CI, 1.02 to 1.53; P =
0.03). To summarize, plasma IL-6 level is an independent and consistent predictor of AF in
patients with CKD.
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Introduction
Atrial fibrillation (AF) is the most common type of arrhythmia, affecting about 0.9% of the
general population.[1,2] AF is associated with high health care system utilization, lower quality
of life, and increased risk for hospitalization, heart failure, stroke and death.[3–5] Compared to
the general population, the prevalence of AF is two to three times higher in those with chronic
kidney disease (CKD).[6–8] In patients with CKD, incident AF is associated with an increase
in mortality and progression to end-stage renal disease.[9,10] Therefore, risk assessment is of
utmost importance in order to improve primary and secondary prevention of AF and its conse-
quences in CKD patients.
Experimental as well as epidemiological studies suggest that inflammation may be involved
in the pathogenesis of AF.[11] Inflammatory biomarkers, including C-reactive protein (CRP),
interleukin (IL)-6, and tumor necrosis factor (TNF)-α are associated with the presence, persis-
tence and outcome of AF in the general population.[12–14] CKD is a well-recognized pro-
inflammatory state with elevated levels of pro-inflammatory cytokines and positive acute phase
proteins.[15] However, no large scale studies have examined the association between AF and
biomarkers of inflammation in CKD patients.
In this study, we examined the hypothesis that inflammation is associated with increased
risk for AF in patients with CKD using the data from the Chronic Renal Insufficiency Cohort
(CRIC) study. The CRIC study is an ongoing, multi-center, multi-ethnic, prospective observa-
tional cohort, established by the National Institute of Health with the goal of identifying the
risk factors for cardiovascular disease (CVD) in patients with CKD.[16] Identifying the specific
cytokine associated with AF may offer new opportunities for diagnosis, risk prediction and
novel therapeutic strategies.
Materials and Methods
Study participants
The CRIC Study is an ongoing multicenter cohort study, in which 3,939 participants were
enrolled from seven clinical centers in the US between June 2003 and August 2008. The organi-
zation, design, and methods of CRIC study have been previously reported.[17] The exclusion
criteria in CRIC were cirrhosis, class III or IV heart failure, human immunodeficiency virus
infection, cancer, autoimmune disease, polycystic kidney disease, pregnancy, post-transplant
patients, current or past immunotherapy within the past six month or systemic chemotherapy.
The study protocol was approved by the Institutional Review Boards at the participating clini-
cal site which were Ann Arbor, Michigan; Baltimore, Maryland; Chicago, Illinois; Cleveland,
Ohio; New Orleans, Louisiana; Philadelphia, Pennsylvania; and Oakland, California. Written
informed consent was obtained from all study participants. (dbGaP Study Accession:
phs000524.v1.p1)
Data collection
Demographic and clinical characteristics were determined at baseline. Serum creatinine was
measured by the Jaffe method on a Beckman Synchron System. Glomerular filtration rate was
calculated using the estimating equation derived from the CRIC cohort (eGFR).[18] Albumin-
uria was estimated as the ratio of albumin to creatinine in the urine (UACR).
Diabetes was defined as fasting glucose 126 mg/d, random glucose 200 mg/dL, or use
of insulin or anti-diabetic medication. Hypertension was defined as systolic blood pressure
(SBP)140 mmHg, and/or diastolic blood pressure (DBP) 90 mm Hg, and/or self-reported
antihypertensive medication use. Echocardiography (echo) was performed within 14 months
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of enrollment in the study according to the recommendations of the American Society of Echo-
cardiography and interpreted at a central laboratory.[19] Left ventricular (LV) mass was calcu-
lated using the area–length method and indexed to height2.7 (LVMI). LV end-diastolic volume
(LVEDV) and LV end-systolic volume (LVESV) were calculated using the modified biplane
method. Ejection fraction was calculated as (LVEDV-LVESV)/LVEDV. Left atrium (LA) diam-
eter was measured in the parasternal long axis view from trailing edge of the posterior aortic
root-anterior LA complex to the posterior LA wall at end-systole.
Measurement of biomarkers of inflammation
Methods to measure inflammatory biomarkers in CRIC study has been described previously.
[15] All cytokine assays were performed in duplicate and mean values were used in the analysis.
High sensitivity sandwich ELISAs (Quantikine HS, R&D Systems, Minneapolis, MN) were
used to measure plasma IL-6, and TNF-α levels. The samples were stored at -80°C and assays
performed at the time of initial thawing. The CV was<13% for all cytokines assays except for
TNF-α and TGF-β, for which the estimated imprecision were 15.2% and 21.5%, respectively.
High sensitivity (hs)-CRP and fibrinogen were quantified in EDTA plasma samples using spe-
cific laser-based immunonephelometric methods on the BNII (Siemens Healthcare Diagnos-
tics, Deerfield, IL). The coefficient of variation for hs-CRP and fibrinogen were< 5%.
Determination of AF
Standard 12-lead electrocardiographs (ECG) were recorded in all participants by strictly stan-
dardized procedures using identical ECG equipment (GE MAC 1200, GE Medical Systems,
Milwaukee, WI). The digitally recorded ECGs were transmitted to a central ECG Reading Cen-
ter. ECGs were analyzed using Minnesota Code for ECG classification.[20] A diagnosis of new-
onset AF required that the participant developed first occurrence of AF during follow-up.
Statistical Analysis
Histograms and Quantile-Quantile (QQ) Plots were examined, and skewed variables were log-
transformed. Most biomarkers were severely skewed with outliers, even after log-transforming.
Therefore, we examined the biomarkers as continuous variable and also as tertiles. Associations
between patient characteristics and baseline AF were tested using chi-square for categorical
variables and independent-groups t-tests for continuous variables. Logistic regression was used
to examine the association of individual inflammatory biomarkers with outcome, adjusting for
covariates. This was done in a phased approach, first testing a model that included patient
demographic characteristics (age, sex, race, body mass index) and comorbid conditions (diabe-
tes mellitus, smoking, history of CVD) in phase one, echocardiographic parameters and medi-
cations in phase two (SBP, eGFR, and use of Angiotensin converting enzyme inhibitor/
Angiotensin receptor blocker [ACEi/ARB], antiplatelet agents, beta-blocker, calcium channel-
blocker, diuretic, insulin, aspirin, and statins), and UACR and potassium in phase three. Pre-
dictors with P<0.10 from phases 1–3 were then used together as covariates to test each inflam-
matory marker in phase four. Interactions between cytokines in the final model and sex and
race were also tested. Weighted regression was used to test for multicollinearity.[21] Tolerance
and variance inflation factor were examined for each variable in the regression model.
For cytokines found to have significant association with new-onset AF after adjusting for
covariates, time from baseline to incident AF was examined by tertile, and differences in time
functions were tested with the log-rank test using Kaplan-Meier analysis. SAS (version 9.2,
Cary, NC) was used for all data analysis, with P<0.05 indicating significance.
Atrial Fibrillation in CKD
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Results
We could not determine current AF status for 177 patients who did not have a baseline ECG
reading, and they were excluded from analyses. A total of 634 participants reported a past his-
tory of AF at baseline, but only 44 had AF by ECG. Table 1 shows the clinical characteristics of
patients with and without AF at baseline based on either self-reported or ECG-diagnosed AF.
Patients with AF were more likely to be older, African Americans, with history of CVD, larger
body mass index (BMI) and lower eGFR. These subjects were more likely to be treated with
Table 1. Baseline characteristics of patients with and without atrial fibrillation*.
Variable AF, n = 642 No AF, n = 3,120 P-value
Age (years) 60.8 ± 9.4 57.0 ± 11.2 <0.001
Female (%) 296 (46.1%) 1398 (44.8%) 0.55
African American (%) 316 (49.2%) 1253 (40.2%) <0.001
Caucasian (%) 270 (42.1%) 1479 (47.4%) 0.013
Hispanic (%) 49 (7.6%) 436 (14.0%) <0.001
Hypertension (%) 563 (87.7%) 2674 (85.7%) 0.19
Diabetes mellitus (%) 332 (51.7%) 1493 (47.9%) 0.08
History of CHF (%) 177 (27.6%) 189 (6.1%) <0.001
History of CVD (%) 377 (58.7%) 883 (28.3%) <0.001
BMI(kg/m2) 32.8 ± 8.2 31.9 ± 7.7 0.005
eGFR (ml/min/1.73 m2) 41.6 ± 13.2 43.1 ± 13.6 0.02
Potassium (mmol/L) 4.3 ± (0.5) 4.4 ± (0.5) 0.04
UACR ug/mg (median, IQR) 44.0 (9.3–367.8) 53.1 (8.3–479.3) 0.12
Log-BNP 4.3 ± 1.4 3.6 ± 1.3 <0.0001
Medication use (%)
ACEi/ARB 456 (71.5%) 2112 (68.2%) 0.10
Antiplatelet agents 335 (52.5%) 1393 (45.0%) <0.001
Beta-blocker 422 (66.1%) 1428 (46.1%) <0.001
Calcium Channel Blocker 277 (43.4%) 1238 (40.0%) 0.11
Diuretic 461 (72.3%) 1767 (57.0%) <0.001
Aspirin 310 (48.6%) 1301 (42.0%) 0.002
Echocardiographic data
EF (%) 51.4 ± 11.4 54.5 ± 7.9 <0.001
LVMI 74.6 ± 27.5 64.2 ± 23.1 <0.001
LA diameter (cm) 4.1 ± 0.7 3.9 ± 0.6 <0.001
Biomarkers
hs-CRP (mg/L) 6.0 ± 9.2 5.5 ± 9.9 0.16
Fibrinogen (g/L) 4.3 ± 1.1 4.1 ± 1.2 <0.001
IL-1β (pg/ml) 1.4 ± 4.2 1.4 ± 4.8 0.9
IL-1RA (pg/ml) 1475.6 ± 2685.0 1421.8 ± 1910.1 0.63
IL-6 (pg/ml) 4.6 ± 13.8 3.4 ± 9.1 0.0079
TNF-α (pg/ml) 2.9 ± 2.7 3.5 ± 13.9 0.02
TGF-β (pg/ml) 13.5 ± 10.8 13.9 ± 11.2 0.50
*AF was defined as having either self-reported or ECG-diagnosed AF.
Data presented as n (%) or mean ± sd. CVD = Cardiovascular disease, CHF = Congestive heart failure, BMI = Body mass index, eGFR = Estimated
glomerular filtration rate, UACR = Urine albumin to creatinine ratio, ACEi/ARB = Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker,
CCB = Calcium channel blockers, EF = Ejection fraction, LVMI = Left ventricular mass index, LA = Left atrium, interleukin = IL, IL-1RA = IL-1 Receptor
antagonist, TNF-α = tumor necrosis factor-α, TGF-β = Transforming growth factor-β, hs-CRP = high sensitivity C-Reactive protein
doi:10.1371/journal.pone.0148189.t001
Atrial Fibrillation in CKD
PLOSONE | DOI:10.1371/journal.pone.0148189 February 3, 2016 4 / 12
beta blockers, antiplatelet agents and diuretics, and more likely to have lower ejection fraction,
higher LVMI and larger LA diameter. Plasma levels of fibrinogen, IL-6 and TNF-α were signifi-
cantly higher in patients with AF.
Atrial fibrillation at baseline
Among the biomarkers studied, highest tertiles of hs-CRP (odds ratio [OR], 1.47; 95% confi-
dence interval [CI], 1.19 to 1.81; P<0.001) and IL-6 (OR, 1.87; 95% CI, 1.50 to 2.32; P<0.001)
had significant univariate associations with past history of AF. However, these associations
were attenuated after adjustment for demographic characteristics, comorbid conditions, echo
parameters, and medications use, and were no longer significant. Among the biomarkers
tested, only IL-6 was significantly associated with AF confirmed by ECG in the fully adjusted
model. (OR, 1.61; 95% CI, 1.21 to 2.14; P = 0.001). (Table 2) The odds for presence of AF by
ECG at baseline was six fold higher for the third tertile of IL-6 compared to the lowest tertile
(OR, 5.89; 95% CI, 1.75 to 19.81; P = 0.004). (Fig 1)
New-onset atrial fibrillation
During a mean follow-up of 3.7 (interquartile range 2.8 to 4.9) years, 108 subjects developed
new-onset AF. Kaplan-Meier (KM) analysis was used to examine time from baseline
Table 2. Association between inflammatory biomarkers and atrial fibrillation diagnosed by ECG.
Unadjusted OR P-value Adjusted OR† P-value
ECG diagnosed AF at baseline
hs-CRP 1.15 (0.91–1.46) 0.24 1.12 (0.86–1.45) 0.40
Fibrinogen 1.12 (0.89–1.42) 0.33 1.06 (0.82–1.37) 0.66
TNF-α 1.22 (0.83–1.81) 0.31 1.01 (0.64–1.60) 0.9
IL-6 1.70 (1.36–2.12) <0.0001 1.61 (1.21–2.14) 0.001
New-onset atrial fibrillation
hs-CRP 1.16 (1.00–1.35) 0.049 1.13 (0.96–1.33) 0.13
Fibrinogen 1.09 (0.93–1.27) 0.28 1.01 (0.86–1.18) 0.9
TNF-α 1.15 (0.89–1.48) 0.29 0.97 (0.73–1.28) 0.82
IL-6 1.37 (1.16–1.63) 0.0007 1.25 (1.02–1.53) 0.03
† Adjusted for age, sex, race, body mass index, diabetes mellitus, smoking, history of CVD, echocardiographic parameters, SBP, eGFR, and use of
Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker [ACEi/ARB], antiplatelet agents, beta-blocker, calcium channel-blocker, diuretic,
insulin, aspirin, and statins, and UACR and potassium.
doi:10.1371/journal.pone.0148189.t002
Fig 1. Unadjusted andmultivariable adjusted association between tertiles of IL-6 and ECG-diagnosed
atrial fibrillation at baseline.
doi:10.1371/journal.pone.0148189.g001
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assessment to incident AF for tertiles of IL-6. The time functions for IL-6 tertiles were signifi-
cantly different (P<0.001; Fig 2). Patients with the highest IL-6 tertile were most likely to have
new-onset of AF during follow-up. In the unadjusted model, hs-CRP (OR, 1.16; 95% CI, 1.00
to 1.35; P = 0.05) and IL-6 (OR, 1.37; 95% CI, 1.16 to 1.63; P<0.001) were associated with new
onset AF. After adjusting for demographic characteristics, comorbid conditions, laboratory val-
ues, echocardiographic variables, and medication use, only IL-6 was associated with new-onset
AF (OR, 1.25; 95% CI, 1.02 to 1.53; P = 0.03). (Table 2) As compared to the lowest tertile, the
highest IL-6 tertile was associated with two-fold increased risk for new-onset AF (OR, 1.94;
95% CI, 1.14 to 3.31; P = 0.02). (Fig 3)
Interactions of cytokine levels with sex and race were not significant. Weighted regression
was used to test for multicollinearity in prediction models for incident AF.[21] In these models
the largest variance inflation was<1.3, indicating that multicollinearity was not distorting the
parameter p-values.
Fig 2. Kaplan-Meier incident atrial fibrillation-free survival estimates by IL-6 tertile. Kaplan Meier AF-free survival estimates for new-onset AF (in
patients who were negative for history of AF or current AF) stratified by IL-6 tertiles. Time to AF differs significantly between tertiles (Log-Rank chi-
square = 24.16, df = 2, P<0.001).
doi:10.1371/journal.pone.0148189.g002
Atrial Fibrillation in CKD
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Discussion
We examined the association of selected biomarkers of inflammation with AF in a large cohort
of CKD subjects with a wide range of kidney function. Among the biomarkers tested, only IL-6
emerged as a strong independent risk factor for AF at baseline visit and new AF. Compared to
those in the lowest tertile, patients in the highest tertile of IL-6 had about 6-fold higher risk for
having AF by ECG at baseline and 2-fold higher risk for new-onset AF during follow-up. The
association between AF and IL-6 remained significant after adjusting for age, sex, race, BMI,
smoking, diabetes mellitus, history of CVD, laboratory variables, SBP, echo parameters, medi-
cation use and kidney function.
CKD is a well-recognized risk factor for incident as well as prevalent AF.[6,9] Among
patients with coronary artery disease, decreased cystatin C–based eGFR and albuminuria are
associated with prevalent AF.[22] In Cardiovascular Health Study participant’s, cystatin C was
associated with prevalent AF, but neither cystatin C nor eGFR were independent predictors of
incident AF.[23] AF has been associated with older age, smoking, male sex and history of
CVD, but not with eGFR among the CRIC study participants.[24] However, a substantial pro-
portion of AF risk cannot be explained by traditional risk factors alone. Other factors such as
inflammation, abnormal cardiac geometry, activation of renin-angiotensin-aldosterone system
and sympathetic over activity could also be potential cause for increased prevalence of AF in
CKD.[25–27] In the present study, we found elevated level of plasma IL-6 to be an independent
and consistent risk factor for AF in CKD patients.
There is an increasing body of evidence linking inflammation to AF. Cytokines are secreted
polypeptides that regulate the inflammatory response through autocrine, paracrine and endo-
crine mechanisms.[28,29] These biomolecules are pleiotropic in their actions, with consider-
able redundancy between their functions.[30] Cytokines may mediate downstream effects
through acute phase proteins such as C-Reactive Protein (CRP) and fibrinogen. Atrial tissue in
patients with AF shows evidence of inflammatory infiltrate.[31] TNF-α induces abnormal cal-
cium signaling and augments arrythmogenicity in isolated rabbit pulmonary vein cardiomyo-
cytes.[32] Findings fromWomen’s Health Study showed that an inflammation score
comprised of plasma levels of hs-CRP, soluble intercellular adhesion molecule 1 (sICAM-1),
and fibrinogen is associated with the risk of incident AF.[33] In Cardiovascular Health Study, a
population-based, longitudinal study of coronary heart disease and stroke in adults aged 65
years and older, CRP was independently associated with baseline as well as future development
of AF.[34] Analysis of ten biomarkers indicative of pathways related to AF in the Framingham
cohort participants identified brain natriuretic peptide as the strongest predictor of incident
AF.[35] CRP was also significantly associated with the outcome, but it did not improve risk
prediction further.[35] A retrospective cross-sectional study in 1,010 CKD patients did not
Fig 3. Unadjusted andmultivariable adjusted association between tertiles of IL-6 and new-onset atrial
fibrillation during follow-up.
doi:10.1371/journal.pone.0148189.g003
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note any association between hs-CRP levels and presence of AF.[36] This is consistent with our
finding in this study.
In multivariate analysis plasma IL-6 is associated with AF at baseline as well as new-onset
AF during follow-up. IL-6 is a pleiotropic cytokine with diverse biological function.[37] It is
produced not only by immune cells, but also by endothelial cells, vascular smooth-muscle
cells, and ischemic myocytes. We recently reported that elevated plasma levels of hs-CRP
and IL-6 are associated with left ventricular hypertrophy and systolic dysfunction in CRIC
study participants.[27] IL-6 has been linked to the initiation and perpetuation of AF in the
setting of coronary heart disease, post-coronary artery bypass grafting, post-cardioversion
and after radiofrequency catheter ablation.[13,38–40] Circulating level of IL-6 is associated
with activation of sympathetic and renin-angiotensin systems as well as LA diameter and
severity of LV dysfunction, which are established risk factors for AF.[41,42] Furthermore,
IL-6 may augment the risk for thromboembolism through increase in expression of fibrino-
gen, tissue factor, factor VIII and von Willebrand factor.[43] Plasma level of CRP, IL-6,
fibrinogen, TNF-α, CD-40 ligand and monocyte chemoattractant protein-1 were measured
in 971 Heart and Soul Study, which consisted of older adults with stable coronary heart dis-
ease.[13] However, after controlling for comorbidities, only IL-6 was significantly associated
with AF.[13]
Elevated plasma level of IL-6 has been found to correlate with increased mortality in general
population, elderly and in patients with CKD.[44–47] Barreto et al noted that IL-6 is a signifi-
cantly better predictor of all cause and cardiovascular mortality than CRP, albumin and TNF-α
in patients with CKD.[48] Zocalli showed that an inflammation score composed of CRP, IL-6,
IL-1, IL-18, and TNF-α predicts death no better than IL-6 alone in ESRD patients.[49] CRP is
elevated in patients with AF and is also a predictive of new onset AF in Cardiovascular Health
Study participants.[34]
We observed a strong association between IL-6 and AF, but not with CRP in CRIC study
participants. CRP is an acute phase protein synthesized primarily by the liver, which is tran-
scriptionally regulated by IL-6. The precise mechanism by which IL-6 and CRP induces AF is
uncertain, but might reflect active participation in atrial remodeling. Indeed, circulating IL-6
level is associated with increased left atrial size, supporting a link between the cytokine and
atrial remodeling.[41] In Multi-Ethnic Study of Atherosclerosis (MESA) study population, ele-
vated IL-6 was associated with depressed LV systolic function, which was shown to be indepen-
dent of known cardiovascular risk factors and CRP.[50] These finding argue that IL-6 may be a
better predictor of the inflammatory effects in the myocardium in the general population as
well as in patients with CKD.
IL-6 signaling directed interventions are most logical strategies for reducing inflammation.
IL-6 first binds to a non-signaling IL-6 Receptor (IL-6R), which, after dimerization with gp130,
leads to activation of receptor-associated kinases within the cell. Interventions directed against
IL-6/gp130 signaling are potential targets for therapy. Besides the humanized IL-6R antibody
tocilizumab, a number of anti–IL-6 molecules are in pipeline.[51] The utility of such therapies
in inflammation associated with CKD remains to be explored.
Our study has a number of strengths, which include (a) a large multiracial cohort of patients
with a broad range of kidney function, (b) detailed and comprehensive data collection, (c) lon-
gitudinal data with a mean follow up of 3.7 years, and (d) examination of a large panel of bio-
markers of inflammation. These findings should be considered within the context of some
limitations: Cytokines were measured only at baseline in our study. However, investigators
have shown that even a single baseline measure could accurately reflect healthy individuals'
inflammatory status over a four to six month period.[52] Although our findings support the
potential role of inflammation in AF, causality remains to be established.
Atrial Fibrillation in CKD
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To summarize, we examined selected inflammatory biomarkers as risk factors for AF in
CRIC study participants and found that only elevated levels of IL-6 is associated with increased
risk for ECG-diagnosed AF at baseline and also new-onset AF during follow-up. Elevated IL-6
may be useful in risk stratification and also as a potential therapeutic target in the management
of high risk CKD patients.
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